Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Addressing sleep apnea early might decrease chances of developing Parkinson's disease - 2Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- 3AbbVie plans to build out its presence in obesity market
- 4A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
- 5Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- 6 Fun Urban areas For Seniors To Travel
- Shrewd Home Gadgets to Save Energy
- The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- The most effective method to Recognize an Excellent Lab Precious stone
- Nestlé recalls infant formula in 49 countries. See list.
- Vote In favor of Your Number one Cell phones
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- Sound Maturing: Wellbeing Tips for Each Life Stage
- Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
